Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.1.6.4 extracted from

  • Rodriguez, A.; Espejo, A.J.; Hernandez, A.; Velasquez, O.L.; Lizaraso, L.M.; Cordoba, H.A.; Sanchez, O.F.; Almeciga-Diaz, C.J.; Barrera, L.A.
    Enzyme replacement therapy for MorquioA: an active recombinant N-acetylgalactosamine-6-sulfate sulfatase produced in Escherichia coli BL21 (2010), J. Ind. Microbiol. Biotechnol., 37, 1193-1201.
    View publication on PubMed

Cloned(Commentary)

Cloned (Comment) Organism
recombinant enzyme expression in Escherichia coli strain BL21 in both soluble and inclusion bodies fractions, rGALNS amounts in inclusion bodies fraction are up to 17fold higher than those observed in the soluble fraction, method optimization, effect of aeration and agitation at bench scale, detailed overview Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens P34059
-
-

Synonyms

Synonyms Comment Organism
GALNS
-
Homo sapiens

General Information

General Information Comment Organism
malfunction mucopolysaccharidosis IVA, MPS IVA, is an autosomal recessive disorder caused by N-acetylgalactosamine-6-sulfate sulfatase deficiency and leading to lysosomal accumulation of the glycosaminoglycans keratan sulfate and chondroitin-6-sulfate Homo sapiens